PCI术后口服不同剂量阿托伐他汀对STEMI患者预后的影响  

Effects of Different Doses of Atorvastatin on the Prognosis of Patients with STEMI After PCI

作　　者：李慧颖[1] 郭新忠[1] 李静[1] 徐霞[1] 

机构地区：[1]山东省医学科学院附属医院,山东济南250031

出　　处：《中国辐射卫生》2016年第2期242-245,共4页Chinese Journal of Radiological Health

摘　　要：目的探讨经皮冠状动脉介入(PCI)术后口服不同剂量阿托伐他汀对急性ST段抬高型心肌梗死(STEMI)患者预后的影响。方法入选118例既往未服用他汀类药物的急性STEMI患者随机两组:观察组60例和对照组58例。观察组患者术后口服阿托伐他汀40 mg/d,1月后改为20 mg/d;对照组患者术后口服阿托伐他汀20 mg/d。观察PCI术后8 h、术后24 h肌酸激酶同工酶(CK-MB)、肌钙蛋白I(c Tn I)及超敏C反应蛋白(hs-CRP)的变化。随访1月记录主要终点事件发生率。结果两组患者CK-MB、cTnI及hs-CRP在PCI术后8 h、PCI术后24 h分别同PCI术前比较,数值明显升高(P<0.05);与对照组比较,观察组CK-MB、c Tn I及hs-CRP增高程度显著降低(P<0.05)。随访1月后,观察组主要终点事件的发生率明显降低(P<0.05)。结论 STEMI患者PCI后口服阿托伐他汀,能减少PCI术后1月主要不良心血管事件的发生。Objective To investigate the effect of different doses of atorvastatin on the prognosis of patients with STEMI after PCI. Methods A total of 118 patients with acute STEMI were selected and then randomly divided into two groups. The observation group （n = 60） was given atorvastatin 40mg/day after PCI and 20rag/day after one months. The control group（ n = 58 ） was given atorvastatin 20 mg/day after PCI. The changes were observed of creatine kinase MB, cardiac troponin I and high - sensitivity C - reactive protein in 8 hours after PCI and 24 hours after PCI. After 1 months of follow - up, the primary end point events were recorded. Results The CK - MB, eTnI and hs - CRP in the two groups were significantly higher in 8 hours after PCI and 24 hours after PCI than those in the preoperative PCI（P 〈0.05）. The levels of CK - MB, cTnI and hs - CRP in the observation group were significantly lower than those in the control group （ P 〈 0.05 ）. Compared with the control group, the incidence of the primary endpoint events in the observation group was statistically significant（ P 〈 0.05 ） after 1 months follow up. Conclusion The treatment of atorvastatin in the patients with STEMI after PCI can significantly reduce the incidence of major adverse cardiovascular events.

关 键 词：经皮冠状动脉介入术 阿托伐他汀 急性ST段抬高型心肌梗死 预后 

分 类 号：R815[医药卫生—放射医学]